| Literature DB >> 9818891 |
L W Myers1, G W Ellison, J E Merrill, A El Hajjar, B St Pierre, M Hijazin, B D Leake, J R Bentson, M R Nuwer, W W Tourtellotte, P Davis, D Granger, J L Fahey.
Abstract
Fourteen MS patients took pentoxifylline at varying doses for up to 24 months. In vitro production of tumor necrosis factor alpha was reduced in patients taking 2,400 to 3,200 mg/day of pentoxifylline for 12 weeks or more. Twelve of the 14 patients experienced worsening of the disease during the study according to clinical, MRI, or visual evoked potential criteria. These results provide no hint of efficacy for pentoxifylline as a treatment for MS in progression phase.Entities:
Mesh：
Substances：
Year: 1998 PMID： 9818891 DOI： 10.1212/wnl.51.5.1483
Source DB: PubMed Journal: Neurology ISSN： 0028-3878 Impact factor: 9.910